Prognostic Analysis and an Appropriate Antiplatelet Strategy for Patients With Percutaneous Coronary Intervention and High Bleeding Risk: Rationale and Protocol for a Multi-Center Cohort Study
Percutaneous coronary intervention (PCI) is an important treatment strategy for patients with coronary artery disease. However, bleeding after PCI significantly increases the mortality risk. The search for prognostic predictors and optimal antiplatelet therapy for patients with high bleeding risk (H...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health/LWW
2024-09-01
|
| Series: | Cardiology Discovery |
| Online Access: | http://journals.lww.com/10.1097/CD9.0000000000000121 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849701478108758016 |
|---|---|
| author | Junyan Zhang Zhongxiu Chen Hua Wang Mian Wang Chen Li Sen He Yong Peng Jiafu Wei Yong He |
| author_facet | Junyan Zhang Zhongxiu Chen Hua Wang Mian Wang Chen Li Sen He Yong Peng Jiafu Wei Yong He |
| author_sort | Junyan Zhang |
| collection | DOAJ |
| description | Percutaneous coronary intervention (PCI) is an important treatment strategy for patients with coronary artery disease. However, bleeding after PCI significantly increases the mortality risk. The search for prognostic predictors and optimal antiplatelet therapy for patients with high bleeding risk (HBR) after PCI has been a much researched upon topic in current cardiovascular research. However, there is no widely accepted prognostic model or recommended antiplatelet therapy for patients with PCI-HBR. In this trial, based on prospective multi-center database building, we will analyze the adverse prognostic predictors for patients with PCI-HBR, observe the types of antiplatelet drugs and duration of dual antiplatelet therapy in PCI-HBR patients, and compare the safety and feasibility of different antiplatelet regimens and treatment courses. The prognostic analysis and an appropriate antiplatelet strategy for patients with PCI and high bleeding risk (PPP-PCI) trial will help analyze bleeding risk factors in PCI-HBR patients and explore the appropriate antiplatelet treatment options. This study is registered with ClinicalTrials.gov (NCT05369442). The Research Ethics Committee of West China Hospital authorized this study (2022 Review #269). The trial results will be published in peer-reviewed journals and at conferences. |
| format | Article |
| id | doaj-art-e43d4c29754747099792ba908d6c204a |
| institution | DOAJ |
| issn | 2096-952X 2693-8499 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Wolters Kluwer Health/LWW |
| record_format | Article |
| series | Cardiology Discovery |
| spelling | doaj-art-e43d4c29754747099792ba908d6c204a2025-08-20T03:17:55ZengWolters Kluwer Health/LWWCardiology Discovery2096-952X2693-84992024-09-014321322010.1097/CD9.0000000000000121202409000-00005Prognostic Analysis and an Appropriate Antiplatelet Strategy for Patients With Percutaneous Coronary Intervention and High Bleeding Risk: Rationale and Protocol for a Multi-Center Cohort StudyJunyan Zhang0Zhongxiu Chen1Hua Wang2Mian Wang3Chen Li4Sen He5Yong Peng6Jiafu Wei7Yong He8Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China.Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China.Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China.Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China.Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China.Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China.Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China.Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China.Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China.Percutaneous coronary intervention (PCI) is an important treatment strategy for patients with coronary artery disease. However, bleeding after PCI significantly increases the mortality risk. The search for prognostic predictors and optimal antiplatelet therapy for patients with high bleeding risk (HBR) after PCI has been a much researched upon topic in current cardiovascular research. However, there is no widely accepted prognostic model or recommended antiplatelet therapy for patients with PCI-HBR. In this trial, based on prospective multi-center database building, we will analyze the adverse prognostic predictors for patients with PCI-HBR, observe the types of antiplatelet drugs and duration of dual antiplatelet therapy in PCI-HBR patients, and compare the safety and feasibility of different antiplatelet regimens and treatment courses. The prognostic analysis and an appropriate antiplatelet strategy for patients with PCI and high bleeding risk (PPP-PCI) trial will help analyze bleeding risk factors in PCI-HBR patients and explore the appropriate antiplatelet treatment options. This study is registered with ClinicalTrials.gov (NCT05369442). The Research Ethics Committee of West China Hospital authorized this study (2022 Review #269). The trial results will be published in peer-reviewed journals and at conferences.http://journals.lww.com/10.1097/CD9.0000000000000121 |
| spellingShingle | Junyan Zhang Zhongxiu Chen Hua Wang Mian Wang Chen Li Sen He Yong Peng Jiafu Wei Yong He Prognostic Analysis and an Appropriate Antiplatelet Strategy for Patients With Percutaneous Coronary Intervention and High Bleeding Risk: Rationale and Protocol for a Multi-Center Cohort Study Cardiology Discovery |
| title | Prognostic Analysis and an Appropriate Antiplatelet Strategy for Patients With Percutaneous Coronary Intervention and High Bleeding Risk: Rationale and Protocol for a Multi-Center Cohort Study |
| title_full | Prognostic Analysis and an Appropriate Antiplatelet Strategy for Patients With Percutaneous Coronary Intervention and High Bleeding Risk: Rationale and Protocol for a Multi-Center Cohort Study |
| title_fullStr | Prognostic Analysis and an Appropriate Antiplatelet Strategy for Patients With Percutaneous Coronary Intervention and High Bleeding Risk: Rationale and Protocol for a Multi-Center Cohort Study |
| title_full_unstemmed | Prognostic Analysis and an Appropriate Antiplatelet Strategy for Patients With Percutaneous Coronary Intervention and High Bleeding Risk: Rationale and Protocol for a Multi-Center Cohort Study |
| title_short | Prognostic Analysis and an Appropriate Antiplatelet Strategy for Patients With Percutaneous Coronary Intervention and High Bleeding Risk: Rationale and Protocol for a Multi-Center Cohort Study |
| title_sort | prognostic analysis and an appropriate antiplatelet strategy for patients with percutaneous coronary intervention and high bleeding risk rationale and protocol for a multi center cohort study |
| url | http://journals.lww.com/10.1097/CD9.0000000000000121 |
| work_keys_str_mv | AT junyanzhang prognosticanalysisandanappropriateantiplateletstrategyforpatientswithpercutaneouscoronaryinterventionandhighbleedingriskrationaleandprotocolforamulticentercohortstudy AT zhongxiuchen prognosticanalysisandanappropriateantiplateletstrategyforpatientswithpercutaneouscoronaryinterventionandhighbleedingriskrationaleandprotocolforamulticentercohortstudy AT huawang prognosticanalysisandanappropriateantiplateletstrategyforpatientswithpercutaneouscoronaryinterventionandhighbleedingriskrationaleandprotocolforamulticentercohortstudy AT mianwang prognosticanalysisandanappropriateantiplateletstrategyforpatientswithpercutaneouscoronaryinterventionandhighbleedingriskrationaleandprotocolforamulticentercohortstudy AT chenli prognosticanalysisandanappropriateantiplateletstrategyforpatientswithpercutaneouscoronaryinterventionandhighbleedingriskrationaleandprotocolforamulticentercohortstudy AT senhe prognosticanalysisandanappropriateantiplateletstrategyforpatientswithpercutaneouscoronaryinterventionandhighbleedingriskrationaleandprotocolforamulticentercohortstudy AT yongpeng prognosticanalysisandanappropriateantiplateletstrategyforpatientswithpercutaneouscoronaryinterventionandhighbleedingriskrationaleandprotocolforamulticentercohortstudy AT jiafuwei prognosticanalysisandanappropriateantiplateletstrategyforpatientswithpercutaneouscoronaryinterventionandhighbleedingriskrationaleandprotocolforamulticentercohortstudy AT yonghe prognosticanalysisandanappropriateantiplateletstrategyforpatientswithpercutaneouscoronaryinterventionandhighbleedingriskrationaleandprotocolforamulticentercohortstudy |